Zanamivir hydrate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581075

CAS#: 551942-41-7 (hydrate)

Description: Zanamivir hydrate is neuraminidase inhibitors (NAIs) and is used worldwide for treatment and prophylaxis of influenza caused by influenza A and B viruses.

Chemical Structure

img
Zanamivir hydrate
CAS# 551942-41-7 (hydrate)
Instruction

Theoretical Analysis

MedKoo Cat#: 581075
Name: Zanamivir hydrate
CAS#: 551942-41-7 (hydrate)
Chemical Formula: C12H22N4O8
Exact Mass: 350.14
Molecular Weight: 350.330
Elemental Analysis: C, 41.14; H, 6.33; N, 15.99; O, 36.53

Price and Availability

Size Price Availability Quantity
250mg USD 400 2 Weeks
1g USD 850 2 Weeks
Bulk inquiry

Related CAS #: 139110-80-8 (free base)   551942-41-7 (hydrate),  

Synonym: Zanamivir hydrate; D01937; J1.917.534K;

IUPAC/Chemical Name: (+)-(4S,5R,6R)-5-Acetylamino-4-guanidino-6-((1R,2R)-1,2,3- trihydroxypropyl)-5,6-dihydro-4H-pyran-2-carboxylic acid hydrate

InChi Key: OELRRAURPSTFEX-VCFRRRQNSA-N

InChi Code: InChI=1S/C12H20N4O7.H2O/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17;/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16);1H2/t5-,6+,8+,9+,10+;/m0./s1

SMILES Code: O=C(C1=C[C@H](NC(N)=N)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1)O.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 350.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T.
Zanamivir for influenza in adults and children: systematic review of clinical
study reports and summary of regulatory comments. BMJ. 2014 Apr 9;348:g2547. doi:
10.1136/bmj.g2547. Review. PubMed PMID: 24811412; PubMed Central PMCID:
PMC3981976.


2: Pizzorno A, Abed Y, Rhéaume C, Boivin G. Oseltamivir-zanamivir combination
therapy is not superior to zanamivir monotherapy in mice infected with influenza
A(H3N2) and A(H1N1)pdm09 viruses. Antiviral Res. 2014 May;105:54-8. doi:
10.1016/j.antiviral.2014.02.017. Epub 2014 Feb 28. PubMed PMID: 24583158.


3: Chan-Tack KM, Kim C, Moruf A, Birnkrant DB. Clinical experience with
intravenous zanamivir under an Emergency IND program in the United States
(2011-2014). Antivir Ther. 2015;20(5):561-4. doi: 10.3851/IMP2944. Epub 2015 Feb
10. Review. PubMed PMID: 25667992.


4: Dunstan HJ, Mill AC, Stephens S, Yates LM, Thomas SH. Pregnancy outcome
following maternal use of zanamivir or oseltamivir during the 2009 influenza
A/H1N1 pandemic: a national prospective surveillance study. BJOG. 2014
Jun;121(7):901-6. doi: 10.1111/1471-0528.12640. Epub 2014 Mar 7. PubMed PMID:
24602087.


5: Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL,
Crawford S, Smee DF, Tucker SP. A zanamivir dimer with prophylactic and enhanced
therapeutic activity against influenza viruses. J Antimicrob Chemother. 2014
Aug;69(8):2164-74. doi: 10.1093/jac/dku127. Epub 2014 Apr 28. PubMed PMID:
24777908; PubMed Central PMCID: PMC4100710.


6: Yang Y, Yang Z, Ren Y, Mei X. Effects of formulation and operating variables
on zanamivir dry powder inhalation characteristics and aerosolization
performance. Drug Deliv. 2014 Sep;21(6):480-6. doi: 10.3109/10717544.2014.883113.
Epub 2014 Feb 4. PubMed PMID: 24491208.


7: Sato M, Honzumi K, Sato T, Hashimoto K, Watanabe M, Miyazaki K, Kawasaki Y,
Hosoya M. Sequential influenza B viral load and susceptibility in children
treated with oseltamivir and zanamivir. Pediatr Infect Dis J. 2014
Jul;33(7):e168-72. doi: 10.1097/INF.0000000000000266. PubMed PMID: 24445826.


8: Lou Y, Gan J, Peppercorn A, Gould E, Weller S, Piscitelli SC, Patel P. Effect
of intravenous zanamivir on cardiac repolarization. Pharmacotherapy. 2013
Jul;33(7):701-9. doi: 10.1002/phar.1261. Epub 2013 Apr 3. PubMed PMID: 23553534.


9: Marty FM, Man CY, van der Horst C, Francois B, Garot D, Mánez R, Thamlikitkul
V, Lorente JA, Alvarez-Lerma F, Brealey D, Zhao HH, Weller S, Yates PJ,
Peppercorn AF. Safety and pharmacokinetics of intravenous zanamivir treatment in
hospitalized adults with influenza: an open-label, multicenter, single-arm, phase
II study. J Infect Dis. 2014 Feb 15;209(4):542-50. doi: 10.1093/infdis/jit467.
Epub 2013 Aug 27. PubMed PMID: 23983212; PubMed Central PMCID: PMC4047294.


10: Tian J, Zhong J, Li Y, Ma D. Organocatalytic and scalable synthesis of the
anti-influenza drugs zanamivir, laninamivir, and CS-8958. Angew Chem Int Ed Engl.
2014 Dec 8;53(50):13885-8. doi: 10.1002/anie.201408138. Epub 2014 Oct 14. PubMed
PMID: 25314609.


11: Shanmugam S. Zanamivir oral delivery: possibilities revisited. Ther Deliv.
2015;6(4):403-5. doi: 10.4155/tde.15.9. PubMed PMID: 25996038.


12: Weight AK, Belser JA, Tumpey TM, Chen J, Klibanov AM. Zanamivir conjugated to
poly-L-glutamine is much more active against influenza viruses in mice and
ferrets than the drug itself. Pharm Res. 2014 Feb;31(2):466-74. doi:
10.1007/s11095-013-1175-4. Epub 2013 Sep 25. PubMed PMID: 24065587; PubMed
Central PMCID: PMC3964776.


13: Shi LL, Cao Y, Zhu XY, Cui JH, Cao QR. Optimization of process variables of
zanamivir-loaded solid lipid nanoparticles and the prediction of their cellular
transport in Caco-2 cell model. Int J Pharm. 2015 Jan 15;478(1):60-9. doi:
10.1016/j.ijpharm.2014.11.017. Epub 2014 Nov 12. PubMed PMID: 25448568.


14: Weller S, Jones LS, Lou Y, Peppercorn A, Ng-Cashin J. Pharmacokinetics of
zanamivir following intravenous administration to subjects with and without renal
impairment. Antimicrob Agents Chemother. 2013 Jul;57(7):2967-71. doi:
10.1128/AAC.02330-12. Epub 2013 Apr 15. PubMed PMID: 23587959; PubMed Central
PMCID: PMC3697365.


15: Zonja B, Gonçalves C, Pérez S, Delgado A, Petrovic M, Alpendurada MF, Barceló
D. Evaluation of the phototransformation of the antiviral zanamivir in surface
waters through identification of transformation products. J Hazard Mater. 2014
Jan 30;265:296-304. doi: 10.1016/j.jhazmat.2013.10.008. Epub 2013 Oct 24. PubMed
PMID: 24211180.


16: Coleman BL, Fadel SA, Drews SJ, Hatchette TF, McGeer AJ. Zanamivir versus
trivalent split virus influenza vaccine: a pilot randomized trial. Influenza
Other Respir Viruses. 2015 Mar;9(2):78-84. doi: 10.1111/irv.12301. Epub 2015 Jan
4. PubMed PMID: 25557838; PubMed Central PMCID: PMC4353320.


17: Schade D, Kotthaus J, Riebling L, Kotthaus J, Müller-Fielitz H, Raasch W,
Hoffmann A, Schmidtke M, Clement B. Zanamivir Amidoxime- and
N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.
J Pharm Sci. 2015 Sep;104(9):3208-19. doi: 10.1002/jps.24508. Epub 2015 Jun 2.
PubMed PMID: 26037932.


18: Morokutti-Kurz M, König-Schuster M, Koller C, Graf C, Graf P, Kirchoff N,
Reutterer B, Seifert JM, Unger H, Grassauer A, Prieschl-Grassauer E, Nakowitsch
S. The Intranasal Application of Zanamivir and Carrageenan Is Synergistically
Active against Influenza A Virus in the Murine Model. PLoS One. 2015 Jun
8;10(6):e0128794. doi: 10.1371/journal.pone.0128794. eCollection 2015. PubMed
PMID: 26053018; PubMed Central PMCID: PMC4459876.


19: Shida Y, Hara K, Nohda S, Soutome T, Hirama T. The pharmacokinetic and safety
profiles of zanamivir after single and repeat intravenous administration in
healthy Japanese males. J Clin Pharm Ther. 2013 Jun;38(3):236-40. doi:
10.1111/jcpt.12056. Epub 2013 Mar 14. PubMed PMID: 23489210.


20: Thai KM, Le DP, Tran NV, Nguyen TT, Tran TD, Le MT. Computational assay of
Zanamivir binding affinity with original and mutant influenza neuraminidase 9
using molecular docking. J Theor Biol. 2015 Nov 21;385:31-9. doi:
10.1016/j.jtbi.2015.08.019. Epub 2015 Sep 1. PubMed PMID: 26341387.